Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15M Buy
116,413
+7,161
+7% +$838K 3.22% 15
2026
Q1
$13.1M Buy
109,252
+1,836
+2% +$212K 3.34% 16
2025
Q4
$11.3M Sell
107,416
-13,464
-11% -$1.26M 2.93% 19
2025
Q3
$10.2M Buy
120,880
+13,017
+12% +$1.07M 2.55% 21
2025
Q2
$8.54M Sell
107,863
-5,611
-5% -$446K 2.6% 25
2025
Q1
$10.2M Buy
113,474
+10,626
+10% +$992K 3.1% 19
2024
Q4
$10.2M Buy
102,848
+390
+0.4% +$40.2K 3.5% 15
2024
Q3
$11.7M Buy
102,458
+3,993
+4% +$474K 3.91% 8
2024
Q2
$12.2M Buy
98,465
+3,978
+4% +$512K 5.09% 4
2024
Q1
$12.5M Buy
94,487
+940
+1% +$116K 6.79% 3
2023
Q4
$10.2M Buy
+93,547
New +$9.71M 6.5% 4

Other funds holding MRK

Eldred Rock Partners's MRK Position: Q2 2026 in Review

Eldred Rock Partners increased its Merck (MRK) stake by 6.6% in Q2 2026, buying an estimated $838K and bringing the position to 116,413 shares worth $15M. The position accounts for 3.22% of the portfolio, ranked #15.

Eldred Rock Partners first reported a position in MRK in Q4 2023 and has held it in 11 quarters since. 3,814 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Eldred Rock Partners held 116,413 shares of Merck worth $15M as of Q2 2026.
  • Eldred Rock Partners bought 7,161 Merck shares in Q2 2026, an estimated $838K.
  • Merck made up 3.22% of Eldred Rock Partners's portfolio in Q2 2026, its #15 holding.
  • Eldred Rock Partners first reported a position in Merck in Q4 2023 and has held it in 11 quarters since.
  • 3,814 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Eldred Rock Partners's 13F filing for Q2 2026, filed 8 Jul 2026.